Alimera Sciences Inc (ALIM)

์ƒ์žฅ๊ฑฐ๋ž˜์†Œ: NASDAQ | ์‚ฐ์—…: ์˜์•ฝํ’ˆ

๊ธฐ์—…๊ฐœ์š”

์ถœ์ฒ˜: ์•ผํ›„ ํŒŒ์ด๋‚ธ์Šค
์ œ์•ฝ ํšŒ์‚ฌ ์ธ Alimera Sciences, Inc.๋Š” ๋ฏธ๊ตญ ๋ฐ ํ•ด์™ธ์—์„œ ์ฒ˜๋ฐฉ ์•ˆ๊ณผ ์šฉ ์˜์•ฝํ’ˆ์˜ ์—ฐ๊ตฌ, ๊ฐœ๋ฐœ ๋ฐ ์ƒ์šฉํ™”์— ์ข…์‚ฌํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ๊ทธ๊ฒƒ์€ ๋ˆˆ์ด๋‚˜ ๋ง๋ง‰์˜ ๋’ค์ชฝ์— ์˜ํ–ฅ์„ ๋ฏธ์น˜๋Š” ์งˆ๋ณ‘์— ์ดˆ์ ์„ ๋งž์ถ”๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ์ด ํšŒ์‚ฌ๋Š” ๋‹น๋‡จ๋ณ‘ ํ™˜์ž์—๊ฒŒ ์˜ํ–ฅ์„ ๋ฏธ์น˜๊ณ  ์‹ฌํ•œ ์‹œ๋ ฅ ์ƒ์‹ค๊ณผ ์‹ค๋ช…์„ ์ดˆ๋ž˜ํ•  ์ˆ˜์žˆ๋Š” ๋ง๋ง‰ ์งˆํ™˜ ์ธ ๋‹น๋‡จ ํ™ฉ๋ฐ˜๋ถ€ ์ข… (DME) ์น˜๋ฃŒ ์šฉ ์œ ๋ฆฌ์ฒด ๊ฐ•๋‚ด ์ด๋ฆฌ ๋นˆ (ILUVIEN)์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. ILUVIEN์€ ๋น„ ์™ธ๊ณผ ์  ์ˆ˜์ˆ ์‹œ ํ™˜์ž์˜ ๋ˆˆ ๋’ค์ชฝ์— ์‚ฝ์ž…๋˜์–ด ๋ˆˆ์— ๋น„ ๋…์ ์  ์ฝ”๋ฅดํ‹ฐ์ฝ” ์Šคํ…Œ๋กœ์ด๋“œ fluocinolone ์•„์„ธํ†  ๋‹ˆ๋“œ์˜ ๋ฏธ์„ธ ๋ฏธ์„ธ ํˆฌ์—ฌ๋ฅผ ๊ณ„์†ํ•จ์œผ๋กœ์จ ์ž์ฒด ๋ฐ€๋ด‰ ์ƒ์ฒ˜๋ฅผ ํ—ˆ์šฉํ•ฉ๋‹ˆ๋‹ค. ์ด ํšŒ์‚ฌ๋Š” pSivida US, Inc.์™€ ILUVIEN์˜ ๊ฐœ๋ฐœ ๋ฐ ํŒ๋งค ๊ณ„์•ฝ์„ ๋งบ์—ˆ์œผ๋ฉฐ ์ธ์ฒด ์•ˆ๊ตฌ ์งˆํ™˜์˜ ์น˜๋ฃŒ ๋ฐ ์˜ˆ๋ฐฉ ๋˜๋Š” DME ์น˜๋ฃŒ๋ฅผ ์œ„ํ•ด ๋‹ค๋ฅธ ์ฝ”๋ฅดํ‹ฐ์ฝ” ์Šคํ…Œ๋กœ์ด๋“œ๋ฅผ ๋ˆˆ ๋’ค์ชฝ์œผ๋กœ ๊ณต๊ธ‰ํ•  ์ˆ˜์žˆ๋Š” ๋…์ ์  ์ธ ์ธ์„œํŠธ ๊ธฐ์ˆ ์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. ํŒ๋งค์›๋ฟ๋งŒ ์•„๋‹ˆ๋ผ ์œ ํ†ต ์—…์ฒด๋ฅผ ํ†ตํ•ด ์ œํ’ˆ์„ ํŒ๋งคํ•ฉ๋‹ˆ๋‹ค. ์ด ํšŒ์‚ฌ๋Š” ์˜์‚ฌ ์‚ฌ๋ฌด์‹ค, ์•ฝ๊ตญ ๋ฐ ๋ณ‘์›์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Alimera Sciences, Inc.๋Š” 2003 ๋…„์— ์„ค๋ฆฝ๋˜์—ˆ์œผ๋ฉฐ ์กฐ์ง€์•„ ์ฃผ ์•ŒํŒŒ ๋ ˆํƒ€์— ๋ณธ์‚ฌ๋ฅผ๋‘๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.

A. ์ฃผ์š”์ง€ํ‘œ

ํŽ€๋”๋ฉ˜ํƒˆ

์ฃผ์š”์ง€ํ‘œ(TTM)
2017/Q3 2018/Q3
PER -9.73 -3.46
PBR 3.99 8.76
PCR -16.50 -4.83
PSR 5.44 2.19
์ฃผ๋‹น๋ฐฐ๋‹น๊ธˆ(๋‹ฌ๋Ÿฌ) 0.00 0.00
๋ฐฐ๋‹น์ˆ˜์ต๋ฅ (%) 0.00 0.00

Wonderful company at Fair price

โ€ป์•„๋ž˜ ์žฌ๋ฌด๋น„์œจ๊ณผ ์‚ฐ์—…ํ‰๊ท  ๊ฐ’์€ 2018๋…„ 3๋ถ„๊ธฐ ๊ธฐ์ค€ TTM(12๊ฐœ์›”) ๊ฐ’์ž…๋‹ˆ๋‹ค.
  • Wonderful company
์ˆ˜์ต์„ฑ & ์„ฑ์žฅ์„ฑ (2018๋…„ 3๋ถ„๊ธฐ ๊ธฐ์ค€)
๋™์ข…์‚ฐ์—…ํ‰๊ท 
ROE(%) -253.48 -78.14
ROIC(%) -76.13 -74.71
EPS์„ฑ์žฅ๋ฅ (%) 0.00 21.37
์•ˆ์ •์„ฑ (2018๋…„ 3๋ถ„๊ธฐ ๊ธฐ์ค€)
๋™์ข…์‚ฐ์—…ํ‰๊ท 
๋ถ€์ฑ„๋น„์œจ(%) 301.66 39.19
์ฐจ์ž…๊ธˆ์˜์กด๋น„์œจ(%) 57.99 1.53
์ด์ž๋ณด์ƒ๋น„์œจ -5.06 -25.03
  • Fair Price
์ ์ •๊ฐ€๊ฒฉ์ง€ํ‘œ (2018๋…„ 3๋ถ„๊ธฐ ๊ธฐ์ค€)
๋™์ข…์‚ฐ์—…ํ‰๊ท 
PER -3.46 -5.93
PEG -12.41 -5.37
EV/EBIT -17.22 -5.34
EV/EBITDA -Inf -0.32

B. ์žฌ๋ฌด์ œํ‘œ

์žฌ๋ฌด์ƒํƒœํ‘œ

(๋‹จ์œ„: 1000๋‹ฌ๋Ÿฌ)
2011 2012 2013 2014 2015 2016 2017
์ด์ž์‚ฐ 34,698 52,521 19,620 108,658 70,484 70,229 59,924
ํ˜„๊ธˆ๋ฐํ˜„๊ธˆ์„ฑ์ž์‚ฐ 33,108 49,564 12,628 76,697 31,075 30,979 24,067
๋งค์ถœ์ฑ„๊ถŒ NA 0 500 850 9,799 13,839 11,435
์žฌ๊ณ ์ž์‚ฐ 0 719 1,786 1,734 1,552 446 1,508
๋‹จ๊ธฐ๊ธˆ์œตํˆฌ์ž์ž์‚ฐ 500 NA NA NA NA NA NA
๊ธฐํƒ€์œ ๋™์ž์‚ฐ 893 2,124 3,724 3,234 2,733 2,138 2,312
์ด์œ ๋™์ž์‚ฐ 34,501 52,407 18,638 82,515 45,159 47,402 39,322
์žฅ๊ธฐ๊ธˆ์œตํˆฌ์ž์ž์‚ฐ NA NA NA NA NA NA NA
์ˆœ์œ ํ˜•์ž์‚ฐ 197 114 982 1,653 2,553 1,787 1,410
๋ฌดํ˜•์ž์‚ฐ NA NA 0 24,490 22,549 20,604 18,664
์˜์—…๊ถŒ NA NA NA NA NA NA NA
์ด๋น„์œ ๋™์ž์‚ฐ 0 0 0 0 223 436 528
์ด๋ถ€์ฑ„ 9,720 13,377 24,545 59,139 44,164 44,643 45,005
๋งค์ž…์ฑ„๋ฌด 1,948 1,973 1,735 5,021 4,002 4,986 5,905
๋‹จ๊ธฐ์ฐจ์ž…๊ธˆ 2,474 2,279 1,677 1,034 32,020 191 184
๋ฏธ์ง€๊ธ‰๊ธˆ 1,638 1,179 934 2,954 3,911 3,758 3,582
๊ธฐํƒ€์œ ๋™๋ถ€์ฑ„ 0 0 0 0 0 0 0
์ด์œ ๋™๋ถ€์ฑ„ 6,718 8,047 4,949 10,475 39,933 9,123 9,671
์žฅ๊ธฐ์ฐจ์ž…๊ธˆ 2,868 703 3,194 32,311 0 33,084 34,365
๊ธฐํƒ€๋น„์œ ๋™๋ถ€์ฑ„ 134 4,627 16,402 16,353 4,231 2,436 969
์ด์ž๋ณธ 24,978 39,144 -4,925 49,519 26,320 25,586 14,919
์ด์šฐ์„ ์ฃผ์ž๋ณธ๊ธˆ 0 32,045 32,045 68,795 68,795 68,795 68,795
์ด๋ณดํ†ต์ฃผ์ž๋ณธ๊ธˆ 24,978 7,099 -36,970 -19,276 -42,475 -43,209 -53,876
๋ณดํ†ต์ฃผ์ž๋ณธ๊ธˆ 236,348 238,215 240,863 294,791 302,573 335,137 346,020
์ด์ต์ž‰์—ฌ๊ธˆ -211,370 -231,116 -277,345 -313,255 -343,900 -377,074 -399,075
์ž์‚ฌ์ฃผ๋งค์ž… NA NA NA NA NA NA NA
๊ธฐํƒ€ํฌ๊ด„์†์ต๋ˆ„๊ณ„์•ก NA 0 -488 -812 -1,148 -1,272 -821
๊ธฐํƒ€์ž๋ณธ NA NA NA NA NA NA NA
๋น„์ง€๋ฐฐ์ง€๋ถ„ NA NA NA NA NA NA NA

์†์ต๊ณ„์‚ฐ์„œ

(๋‹จ์œ„: 1000๋‹ฌ๋Ÿฌ)
2011 2012 2013 2014 2015 2016 2017
์ด๋งค์ถœ NA NA 1,872 8,423 22,438 34,333 35,912
๋งค์ถœ์›๊ฐ€ NA NA 1,863 1,442 1,762 2,344 3,438
๋งค์ถœ์ด์ด์ต NA 0 9 6,981 20,676 31,989 32,474
๊ฐ๊ฐ€์ƒ๊ฐ๋น„ NA NA 138 659 2,555 2,767 2,684
ํŒ๋งค๊ด€๋ฆฌ๋น„ 21,407 22,039 34,413 39,928 59,675 59,836 48,926
์˜์—…์ด์ต -21,407 -22,039 -34,404 -32,947 -38,999 -27,847 -16,452
์ด์ž๋น„์šฉ 1,125 790 686 2,530 4,693 7,742 5,579
๊ธฐํƒ€์ˆ˜์ต -1,109 -790 -11,825 -2,789 8,484 -5,155 -5,386
๋ฒ•์ธ์„ธ๋น„์šฉ์ฐจ๊ฐ์ „์ด์ต -22,516 -22,829 -46,229 -35,736 -30,515 -33,002 -21,838
๋ฒ•์ธ์„ธ๋น„์šฉ NA NA 0 174 130 172 163
๋‹น๊ธฐ์ˆœ์ด์ต -22,516 -19,746 -46,229 -35,910 -30,645 -33,174 -22,001
๊ณ„์†์˜์—…์ด์ต -22,516 -19,746 -51,179 -36,660 -30,645 -33,174 -22,001
์ค‘๋‹จ์‚ฐ์—…์ด์ต NA NA NA NA NA NA NA
๋น„์ง€๋ฐฐ๋‹น๊ธฐ์ˆœ์ด์ต NA NA NA NA NA NA NA

ํ˜„๊ธˆํ๋ฆ„ํ‘œ

(๋‹จ์œ„: 1000๋‹ฌ๋Ÿฌ)
2011 2012 2013 2014 2015 2016 2017
์˜์—…ํ™œ๋™ํ˜„๊ธˆํ๋ฆ„ -20,716 -21,182 -37,821 -24,301 -45,364 -25,099 -12,874
๋‹น๊ธฐ์ˆœ์ด์ต -22,516 -19,746 -46,229 -35,910 -30,645 -33,174 -22,001
๋น„ํ˜„๊ธˆ์กฐ์ • 1,871 -1,306 14,179 5,406 -7,695 4,970 4,822
๊ฐ๊ฐ€์ƒ๊ฐ 419 321 297 1,125 3,391 3,805 4,100
์šด์ „์ž๋ณธ์ฆ๊ฐ -490 -451 -6,068 5,078 -10,415 -700 205
์ด์ž์ง€๊ธ‰ 656 549 607 1,247 4,177 3,958 4,117
์ด์ž์ˆ˜์ทจ NA NA NA NA NA NA NA
๋ฒ•์ธ์„ธ๋‚ฉ๋ถ€์•ก NA NA 0 0 263 193 74
๋Œ€์†์ถฉ๋‹น๊ธˆ NA NA NA NA NA NA NA
ํˆฌ์žํ™œ๋™ํ˜„๊ธˆํ๋ฆ„ 25,720 477 -973 -25,842 -451 -186 -238
์œ ํ˜•์ž์‚ฐ์ฒ˜๋ถ„ NA NA NA NA NA NA NA
ํˆฌ์ž์ƒํ’ˆ์ฒ˜๋ถ„ 25,830 500 NA NA NA NA NA
์œ ํ˜•์ž์‚ฐ์ทจ๋“ -110 -23 -973 -842 -451 -186 -238
ํˆฌ์ž์ƒํ’ˆ์ทจ๋“ NA NA NA NA NA NA NA
๊ธฐํƒ€ํˆฌ์žํ™œ๋™ 0 0 0 -25,000 0 0 0
์žฌ๋ฌดํ™œ๋™ํ˜„๊ธˆํ๋ฆ„ -410 37,161 1,654 114,745 625 25,424 5,723
์ฃผ์‹๋ฐœํ–‰ 154 38 53 37,598 1,002 27,763 6,084
์‚ฌ์ฑ„๋ฐœํ–‰ NA 0 5,000 35,000 NA 6 3
์ฃผ์‹์ทจ๋“ NA -455 0 -2,389 -27 -1,341 -183
๋ถ€์ฑ„์ƒํ™˜ -819 -2,474 -3,471 -6,133 -594 -1,296 -182
๋ฐฐ๋‹น๊ธ‰์ง€๊ธ‰ NA NA NA NA NA NA NA
๊ธฐํƒ€์žฌ๋ฌดํ™œ๋™ 255 52 72 774 571 292 1
์™ธํ™”ํ™˜์ƒ์œผ๋กœ์ธํ•œํ˜„๊ธˆ์˜๋ณ€๋™ NA 0 204 -533 -432 -235 477
ํ˜„๊ธˆ์˜์ฆ๊ฐ 4,594 16,456 -36,936 64,069 -45,622 -96 -6,912

C. ๋‚ด๋ถ€/๊ธฐ๊ด€ํˆฌ์ž์ž

๋‚ด๋ถ€์ž ๊ฑฐ๋ž˜๋‚ด์—ญ

๊ธฐ๊ด€ํˆฌ์ž์ž

D. ๋‰ด์Šค

โ€ป2018๋…„ 12์›” 1์ผ ๊ธฐ์ค€ ์ตœ๊ทผ 15๊ฐœ์˜ ๋‰ด์Šค๋ฅผ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค.
๋‚ ์งœ ์ œ๋ชฉ summary url
2018-11-29 Alimera Sciences, Rick Eiswirth๋ฅผ CEO๋กœ ์ž„๋ช… 2018 ๋…„ 11 ์›” 29 ์ผ / ATOMTA / 2018 ๋…„ 11 ์›” 29 ์ผ / ์ฒ˜๋ฐฉ์ „ ์•ˆ๊ณผ ์šฉ ์˜์•ฝํ’ˆ์˜ ์ƒ์—…ํ™” ๋ฐ ๊ฐœ๋ฐœ ๋ถ„์•ผ์˜ ์„ ๋‘ ์ฃผ์ž ์ธ Alimera Sciences, Inc. (ALIM) (Alimera)๋Š” ํšŒ์‚ฌ์˜ ์ด์‚ฌํšŒ๊ฐ€ Rick Eiswirth๋ฅผ CEO๋กœ ์ž„๋ช…ํ–ˆ๋‹ค๊ณ  ๋ฐœํ‘œํ–ˆ๋‹ค. 2019 ๋…„ 1 ์›” 2 ์ผ๋ถ€ํ„ฐ ์ž„์›์œผ๋กœ ์ž„๋ช…๋ฉ๋‹ˆ๋‹ค. Eiswirth๋Š” ํšŒ์‚ฌ์˜ ์ผ์ƒ์ ์ธ ๋ฆฌ๋”์‹ญ์„ ์œ ์ง€ํ•˜๊ณ  ํšŒ์žฅ ์ง์„ ์œ ์ง€ํ•˜๋ฉฐ Alimera ์ด์‚ฌํšŒ์— ํ•ฉ๋ฅ˜ํ•˜๊ฒŒ๋ฉ๋‹ˆ๋‹ค. https://finance.yahoo.com/news/alimera-sciences-appoints-rick-eiswirth-121500391.html?.tsrc=rss
2018-11-26 Alimera Sciences, ILUVIEN (R)์˜ ์บ๋‚˜๋‹ค ๊ทœ์ œ ์Šน์ธ ๋ฐœํ‘œ ๋ฏธ๊ตญ, ์ฒ˜๋ฐฉ์ „ ์•ˆ๊ณผ ์šฉ ์˜์•ฝํ’ˆ์˜ ์ƒ์—…ํ™” ๋ฐ ๊ฐœ๋ฐœ ๋ถ„์•ผ์˜ ์„ ๋‘ ์ฃผ์ž ์ธ Alimera Sciences, Inc. (ALIM) (Alimera)๋Š” ์˜ค๋Š˜ ์บ๋‚˜๋‹ค ๋ณด๊ฑด๋ถ€ (Health Canada)๊ฐ€ ๋‹น๋‡จ๋ณ‘ ํ™ฉ๋ฐ˜๋ณ€์ฆ ์น˜๋ฃŒ์ œ ILUVIENยฎ์„ ์Šน์ธํ–ˆ๋‹ค๊ณ  ๋ฐœํ‘œํ–ˆ๋‹ค. ๋ถ€์ข… (DME). ILUVIEN์€ ์ด์ „์— ์ฝ”๋ฅดํ‹ฐ์ฝ” ์Šคํ…Œ๋กœ์ด๋“œ๋กœ ์น˜๋ฃŒ ๋ฐ›์•˜๊ณ  ์•ˆ์••์ด ์ž„์ƒ ์ ์œผ๋กœ ์œ ์˜ํ•˜๊ฒŒ ์ƒ์Šนํ•˜์ง€ ์•Š์€ ํ™˜์ž์—์„œ DME๋ฅผ ์น˜๋ฃŒํ•˜๊ธฐ ์œ„ํ•ด ๋ฏธ๊ตญ์—์„œ ์Šน์ธ ๋œ fluocinolone acetonide ์„œ๋ฐฉ ํ˜• ์œ ๋ฆฌ์ฒด ๊ฐ•๋‚ด ์ด์‹ ๋ฌผ์ด๋‹ค. Alimera๋Š” 2015 ๋…„ 7 ์›” Knight Therapeutics, Inc. (์ดํ•˜ โ€œ๊ธฐ์‚ฌโ€)์™€ ILUVIEN์— ๋Œ€ํ•œ ๋…์ ์  ์บ๋‚˜๋‹ค ๊ณ„์•ฝ์„ ์ฒด๊ฒฐํ–ˆ์Šต๋‹ˆ๋‹ค. https://finance.yahoo.com/news/alimera-sciences-announces-canadian-regulatory-203000152.html?.tsrc=rss
2018-11-21 ํ†ตํ•ฉ ๋ฆฌ์„œ์น˜ : 2018 ํ…์‚ฌ์Šค ์ธ์ŠคํŠธ๋ฃจ๋จผ์ธ , Sino-Global Shipping America, Alimera Sciences, Sypris Solutions, JetPay ๋ฐ ์žฌ๋ฌด ์‹ค์  ๋ถ„์„, ํ•ต์‹ฌ ์„ฑ๊ณผ ์ง€ํ‘œ์— ๋Œ€ํ•œ ์š”์•ฝ ๋‰ด์š•, 2018 ๋…„ 11 ์›” 21 ์ผ - ์˜ค๋Š˜ ์•„์นจ ์ผ์ฐ ๋ฐœํ‘œ ๋œ ์ƒˆ๋กœ์šด ๋…๋ฆฝ์  ์ธ ์—ฐ๊ตฌ ๋ณด๊ณ ์„œ์—์„œ Market Source Research๋Š” ๋ชจ๋“  ํ˜„์žฌ ํˆฌ์ž์ž๋ฅผ์œ„ํ•œ ์ตœ์‹  ํ•ต์‹ฌ ๊ฒฐ๊ณผ๋ฅผ ๋ฐœํ‘œํ–ˆ์Šต๋‹ˆ๋‹ค. https://finance.yahoo.com/news/consolidated-research-2018-summary-expectations-132500823.html?.tsrc=rss
2018-11-19 ALIM ์‹ค์  ์ปจํผ๋Ÿฐ์Šค ์ „ํ™” ๋˜๋Š” ํ”„๋ฆฌ์   ํ…Œ์ด์…˜ 6 ์›” 11 ์ผ ์˜คํ›„ 2:00 GMT ์ˆ˜์ • Q3 2018 ์•Œ๋ฆฌ ๋ฉ”๋ผ ์‚ฌ์ด์–ธ์Šค Inc ์ˆ˜์ž… ์ „ํ™” https://finance.yahoo.com/news/edited-transcript-alim-earnings-conference-181013896.html?.tsrc=rss
2018-11-09 Alimera Sciences, ๋‹ค๊ฐ€์˜ค๋Š” ํˆฌ์ž์ž ์ปจํผ๋Ÿฐ์Šค์— ๋ฐœํ‘œ AT & T, 2018 ๋…„ 11 ์›” 9 ์ผ / ์•Œ๋ฆฌ ๋ฉ”๋ผ ์‚ฌ์ด์–ธ์Šค (Alimera Sciences, Inc., NASDAQ : ALIM)๋Š” ์ฒ˜๋ฐฉ์ „ ์•ˆ๊ณผ ์šฉ ์˜์•ฝํ’ˆ์˜ ์ƒ์—…ํ™” ๋ฐ ๊ฐœ๋ฐœ ๋ถ„์•ผ์˜ ์„ ๋‘ ์ฃผ์ž์ž…๋‹ˆ๋‹ค. https://finance.yahoo.com/news/alimera-sciences-present-upcoming-investor-113000098.html?.tsrc=rss
2018-11-06 Alimera Sciences (ALIM), 3 ๋ถ„๊ธฐ ๋งค์ถœ ๋ฐ ๋งค์ถœ ์ถ”์ •์น˜ ๋ฐœํ‘œ Alimera Sciences (ALIM)๋Š” 2018 ๋…„ 9 ์›” ๋๋‚œ ๋ถ„๊ธฐ์— ๊ฐ๊ฐ 16.67 %์™€ 0.15 %์˜ ์ˆ˜์ต๊ณผ ๋งค์ถœ ๋†€๋ผ์›€์„ ๋‚˜ํƒ€ ๋ƒˆ์Šต๋‹ˆ๋‹ค.์ด ์ˆ˜์น˜๋Š” ์ฃผ์‹์— ๋Œ€ํ•œ ์•ž์œผ๋กœ์˜ ์˜ˆ์ธก์— ๋Œ€ํ•œ ๋‹จ์„œ๋ฅผ ์ œ๊ณตํ•ฉ๋‹ˆ๊นŒ? https://finance.yahoo.com/news/alimera-sciences-alim-reports-q3-123012939.html?.tsrc=rss
2018-11-06 Alimera Sciences : 3 ๋ถ„๊ธฐ ์‹ค์  ์Šค๋ƒ… ์ƒท ์กฐ์ง€์•„์ฃผ์˜ ์•ŒํŒŒ ๋ ˆํƒ€ (Alpharetta)์— ๋ณธ์‚ฌ๋ฅผ ๋‘” ํšŒ์‚ฌ๋Š” ์ฃผ๋‹น 39 ์„ผํŠธ์˜ ์†์‹ค์„ ๊ธฐ๋กํ–ˆ๋‹ค๊ณ  ๋ฐํ˜”๋‹ค. ๋น„ ๋ฐ˜๋ณต ์ด์ต์„ ์œ„ํ•ด ์กฐ์ • ๋œ ์†์‹ค์€ ์ฃผ๋‹น 5 ์„ผํŠธ์˜€์Šต๋‹ˆ๋‹ค. ๊ทธ ๊ฒฐ๊ณผ๋Š” ์›”์ŠคํŠธ๋ฆฌํŠธ์˜ ๊ธฐ๋Œ€๋ฅผ ๋›ฐ์–ด ๋„˜์—ˆ์Šต๋‹ˆ๋‹ค. ํ‰๊ท  โ€ฆ https://finance.yahoo.com/news/alimera-sciences-3q-earnings-snapshot-100310987.html?.tsrc=rss
2018-11-05 Alimera Sciences, 2018 ๋…„ 3 ๋ถ„๊ธฐ ๊ฒฐ๊ณผ๋ณด๊ณ  2018 ๋…„ 3 ๋ถ„๊ธฐ์— 11.1 ๋ฐฑ๋งŒ ๋‹ฌ๋Ÿฌ์˜ ์ˆœ ์ˆ˜์ž… ๊ธฐ๋ก; 2018 ๋…„ 3 ๋ถ„๊ธฐ ๋ฏธ๊ตญ์˜ ์ตœ์ข… ์ˆ˜์ž… 20 % ์ฆ๊ฐ€๋กœ ์ˆœ์†์‹ค ๋ฐ ์กฐ์ • EBITDA ์†์‹ค ์ง€์†, ATLANTA, GA / ACCESSWIRE / November โ€ฆ https://finance.yahoo.com/news/alimera-sciences-reports-third-quarter-234500410.html?.tsrc=rss
2018-10-23 Alimera Sciences, 2018 ๋…„ 3 ๋ถ„๊ธฐ ๊ฒฐ๊ณผ ๋ฐœํ‘œ 2018 ๋…„ 11 ์›” 5 ์ผ AT & T, 2018 ๋…„ 10 ์›” 23 ์ผ / ์•Œ๋ฆฌ ๋ฉ”๋ผ ์‚ฌ์ด์–ธ์Šค (Alimera Sciences, Inc., NASDAQ : ALIM)๋Š” ์ฒ˜๋ฐฉ์ „ ์•ˆ๊ณผ ์šฉ ์˜์•ฝํ’ˆ์˜ ์ƒ์—…ํ™” ๋ฐ ๊ฐœ๋ฐœ ๋ถ„์•ผ์˜ ์„ ๋‘ ์ฃผ์ž์ž…๋‹ˆ๋‹ค. https://finance.yahoo.com/news/alimera-sciences-report-third-quarter-204500363.html?.tsrc=rss
2018-10-22 Alimera Sciences, 2018 ๋…„ American Academy of Ophthalmology์—์„œ ILUVIEN (R) ํฌ์Šคํ„ฐ 6 ์ข… ๋ฐœํ‘œ 2018 ๋…„ 10 ์›” 22 ์ผ / ATLANTA, GA / ACCESSWIRE / 2018 ๋…„ 10 ์›” 22 ์ผ / ์ฒ˜๋ฐฉ์ „ ์•ˆ๊ณผ ์šฉ ์˜์•ฝํ’ˆ์˜ ์ƒ์—…ํ™” ๋ฐ ๊ฐœ๋ฐœ ๋ถ„์•ผ์˜ ์„ ๋‘ ์ฃผ์ž ์ธ Alimera Sciences, Inc. (Alimera)๋Š” ์˜ค๋Š˜ ILUVIENยฎ์— ๋Œ€ํ•œ ํฌ์Šคํ„ฐ 6 ์ข…์„ 2018 ๋…„ 10 ์›” 26 ์ผ๋ถ€ํ„ฐ 30 ์ผ๊นŒ์ง€ ์‹œ์นด๊ณ ์˜ ๋งฅ์ฝ”๋ฏน ํ”Œ๋ ˆ์ด์Šค (McCormick Place)์—์„œ ์—ด๋ฆฐ ๋ฏธ๊ตญ ์•ˆ๊ณผ ํ•™ํšŒ (AAO) ํšŒ์˜. ๋˜ํ•œ, Alimera๋Š” ํšŒ์˜์—์„œ ๊ต์œก ํ–‰์‚ฌ๋ฅผ ํ›„์›ํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค. Alimera์˜ CEO ์ธ Dan Myers๋Š” โ€œ์•ž์œผ๋กœ๋„ ๊ณ„์† ์ง„ํ–‰๋  PALADIN ์—ฐ๊ตฌ์˜ ํฌ์Šคํ„ฐ ๋‘ ์žฅ์„ ํฌํ•จํ•˜์—ฌ ILUVIEN์— ๋Œ€ํ•œ ํฅ๋ฏธ๋กœ์šด ๋ฐ์ดํ„ฐ๋ฅผ ์ง€์†์ ์œผ๋กœ ์ƒ์„ฑํ•ฉ๋‹ˆ๋‹ค. https://finance.yahoo.com/news/alimera-sciences-announces-six-iluvien-203000752.html?.tsrc=rss
2018-10-17 EyePoint (EYPT), ์•ˆ๊ณผ ์น˜๋ฃŒ๋ฅผ์œ„ํ•œ FDA ์Šน์ธ ํš๋“ Yutiq EyePoint Pharmaceuticals Inc EYPT๋Š” FDA๊ฐ€ ๋ˆˆ์˜ ๋’ค์ชฝ ๋ถ€๋ถ„์— ์˜ํ–ฅ์„ ๋ฏธ์น˜๋Š” ๋งŒ์„ฑ ๋น„ ์ „์—ผ์„ฑ ํฌ๋„๋ง‰์—ผ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•ด Yutiq fluocinolone acetonide ์œ ๋ฆฌ์ฒด ๊ฐ•๋‚ด ์ด์‹ ๋ฌผ์„ ์Šน์ธํ–ˆ๋‹ค๊ณ  ๋ฐœํ‘œํ–ˆ์Šต๋‹ˆ๋‹ค. Yutiq์€ EyePoint์˜ Durasert ์•ฝํ’ˆ์„ ์‚ฌ์šฉํ•˜๋Š” ์ดˆ์†Œํ˜• ๋งˆ์ดํฌ๋กœ ์ธ์„œํŠธ์ž…๋‹ˆ๋‹ค http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MTxT8xxi_1Q/eyepoint-eypt-gets-fda-approval-for-eye-therapy-yutiq-cm1038624
2018-10-15 Alimera Sciences Inc (NASDAQ : ALIM)์˜ ํฌํŠธํด๋ฆฌ์˜ค ๋ณ€๋™์„ฑ์— ๋ฏธ์น˜๋Š” ์˜ํ–ฅ Alimera Sciences Inc (NASDAQ : ALIM)๋ฅผ ์—ฐ๊ตฌํ•˜๋Š” ์‚ฌ๋žŒ์€ ์ฃผ๊ฐ€์˜ ์—ญ์‚ฌ์  ๋ณ€๋™์„ฑ์„ ๊ณ ๋ คํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํœ˜๋ฐœ์„ฑ์€ ํ˜„๋Œ€ ๊ธˆ์œต ์ด๋ก ์—์„œ ์œ„ํ—˜์˜ ์ฒ™๋„๋กœ ๊ฐ„์ฃผ๋ฉ๋‹ˆ๋‹ค. ์ž์„ธํžˆ โ€ฆ https://finance.yahoo.com/news/alimera-sciences-inc-nasdaq-alim-195744452.html?.tsrc=rss

E. ๊ธฐํƒ€์žฌ๋ฌด๋น„์œจ

โ€ป์•„๋ž˜ ์žฌ๋ฌด๋น„์œจ์€ 2018๋…„ 3๋ถ„๊ธฐ ๊ธฐ์ค€ ๊ฐ’์ž…๋‹ˆ๋‹ค.
์ˆ˜์ต์„ฑ&์„ฑ์žฅ์„ฑ
ROA -0.36
๋งค์ถœ์„ฑ์žฅ๋ฅ  0.09
์„ธํ›„์ˆœ์˜์—…์ด์ต์„ฑ์žฅ๋ฅ  0.04
์ž‰์—ฌํ˜„๊ธˆํ๋ฆ„์„ฑ์žฅ๋ฅ  0.05
๋‹น๊ธฐ์ˆœ์ด์ต์„ฑ์žฅ๋ฅ  -0.08
์•ˆ์ •์„ฑ
Debt_to_Nopat 0.00
Altmanzscore 4.10
์žฌ๋ฌด๋ ˆ๋ฒ„๋ฆฌ์ง€๋น„์œจ -1.27
์œ ๋™๋น„์œจ 19.36
ํšจ์œจ์„ฑ
์ด์ž์‚ฐํšŒ์ „์œจ 0.13
ํˆฌํ•˜์ž๋ณธํšŒ์ „์œจ -0.66
๋งค์ถœ์ฑ„๊ถŒํšŒ์ „์œจ NA
๋งค์ž…์ฑ„๋ฌดํšŒ์ „์œจ NA
์žฌ๊ณ ์ž์‚ฐํšŒ์ „์œจ NA

F. ์žฌ๋ฌด๋น„์œจ์„ค๋ช